| Bioactivity | Tilavonemab (ABBV-8E12) is a humanised anti-tau antibody that binds amino acids 25-30 near the N-terminal end of the tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates and reduces brain atrophy. Tilavonemab can be used in the study of Alzheimer's disease[1]. |
| Target | tau. |
| Name | Tilavonemab |
| CAS | 2096513-89-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Vaswani P A, et al. Immunotherapy in progressive supranuclear palsy. Curr Opin Neurol. 2020 Aug;33(4):527-533. |